A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications
This study is testing a new medication called STK-012, both by itself and mixed with standard cancer treatments. Researchers want to see if this new approach can help treat advanced lung cancer more effectively.
You might be able to join if you have advanced non-small cell lung cancer that has not been treated with full-body therapies before. There are some rules about past treatments and other health conditions to keep you safe.
Depending on the study phase, you will receive either the study medication alone or in combination with standard chemotherapy and immunotherapy drugs. Your health team will monitor you closely throughout the process.
This study is currently recruiting participants at locations in Arizona and California, United States.
- 1Tests a new investigational medication called STK-012
- 2Focuses on newly diagnosed, advanced lung cancer
- 3Combines the new drug with standard chemotherapy and immunotherapy
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.